The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies

mAbs

Volumn 4, Issue 5, 2012, Pages 623-631

  Fischer, Saloumeh K ^a   Yang, Jihong ^a   Anand, Banmeet ^a   Cowan, Kyra ^a   Hendricks, Robert ^a   Li, Jing ^a   Nakamura, Gerald ^a   Song, An ^a  

^a GENENTECH INC   (United States)

Author keywords

CD20 interference; Free or total drug; Monoclonal anti drug CDR (MAC) assay; Pharmacodynamic (PD); Pharmacokinetic (PK); PK assay; Polyclonal anti drug CDR (PAC) assay

Indexed keywords

CD20 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; OCRELIZUMAB; POLYCLONAL ANTIBODY; RITUXIMAB;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PLASMA CONCENTRATION-TIME CURVE; RHEUMATOID ARTHRITIS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 84866559470     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.20814     Document Type: Article

References (13)

1. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2010; 2:1125-40; PMID:21083212; http://dx.doi.org/10.4155/bio.10.64.
2. Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J 2011; 13:99- 110; PMID:21240643; http://dx.doi.org/10.1208/s12248-011-9251-3.
3. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34:10474-82; PMID:7654701; http://dx.doi.org/10.1021/ bi00033a020.
4. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Bio Drugs 2011; 25:13-25; PMID:21090841; http://dx.doi.org/10.2165/11539590.
5. Friedberg JW, Vose JM, Kahl BS, Brunvand MW, Goy A, Kasamon YL, et al. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20-indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. ASH Annual Meeting. New Orleans, LA: Blood 2009; 3742.
6. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, et al.; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:2652-61; PMID:18759293; http://dx.doi.org/10.1002/art. 23732.
7. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47:1119-28; PMID:17766699; http://dx.doi.org/10.1177/0091270007305297.
8. Morschhauser F, Marlton P, Vitolo U, Lindén O, Seymour JF, Crump M, et al. Results of a phase I/ II study of ocrelizumab, a fully humanized anti- CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010; 21:1870-6; PMID:20157180; http://dx.doi.org/10.1093/annonc/mdq027.
9. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 2003; 123:850-7; PMID:14632776; http://dx.doi.org/10. 1046/j.1365-2141.2003.04683.x.
10. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101:2507-13; PMID:12446458; http://dx.doi.org/10.1182/blood-2002-06-1639.
11. Keating MJ, O'Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 2002; 29:70-4; PMID:11842391; http://dx.doi.org/10.1053/sonc.2002.30142.
12. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000; 27:17-24; PMID:11225995.
13. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45:792-801; PMID:15951469; http://dx.doi.org/10.1177/0091270005277075.